Taicbun Qin
FDA investigator
Appears on 1 document from 2017, mostly at sites in California. Most often cites control of microbiological contamination (21 CFR 211.113).
- 1
- Documents on file
- 8.0
- Observations per 483
- 2017
- First seen
- 2017
- Most recent
What they cite most
From 8 observations- 21 CFR 211.113Control of microbiological contamination2
- 21 CFR 211.125Labeling issuance1
- 21 CFR 211.167Special testing requirements1
- 21 CFR 211.42Design and construction features1
- 21 CFR 211.94Drug product containers and closures1
Activity by year
2017: 1
Where
California 1
Often inspects with
Is Taicbun Qin coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
1 document, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2017-03-23 | 483 Fusion IV Pharmaceuticals, Inc. dba Axia PharmaceuticalMar 23, 2017 · Los Angeles, California | Los Angeles, California | 8 |
About this profile
What does Taicbun Qin inspect?
Taicbun Qin appears on 1 document on file covering 1 site, mostly in California.
What do they cite most often?
21 CFR 211.113 (control of microbiological contamination), followed by 21 CFR 211.125 and 21 CFR 211.167.
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Taicbun Qin is dated Mar 23, 2017.